Bone Morphogenetic Protein Receptors, Type II
"Bone Morphogenetic Protein Receptors, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of bone morphogenetic protein receptors with low affinity for BONE MORPHOGENETIC PROTEINS. They are constitutively active PROTEIN-SERINE-THREONINE KINASES that can interact with and phosphorylate TYPE I BONE MORPHOGENETIC PROTEIN RECEPTORS.
| Descriptor ID |
D052006
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.109.750 D12.776.543.750.750.400.049.750
|
| Concept/Terms |
Bone Morphogenetic Protein Receptors, Type II- Bone Morphogenetic Protein Receptors, Type II
- BMP Type II Receptors
- Receptor, Type II BMP
- BMPR2 Receptor
- Receptor, BMPR2
- Bone Morphogenetic Protein Receptor II
- Bone Morphogenetic Protein Receptor Type II
- BMP Type II Receptor
- BMPR-II Receptor
- BMPR II Receptor
- Receptor, BMPR-II
|
Below are MeSH descriptors whose meaning is more general than "Bone Morphogenetic Protein Receptors, Type II".
Below are MeSH descriptors whose meaning is more specific than "Bone Morphogenetic Protein Receptors, Type II".
This graph shows the total number of publications written about "Bone Morphogenetic Protein Receptors, Type II" by people in this website by year, and whether "Bone Morphogenetic Protein Receptors, Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bone Morphogenetic Protein Receptors, Type II" by people in Profiles.
-
PTPN1 Deficiency Modulates BMPR2 Signaling and Induces Endothelial Dysfunction in Pulmonary Arterial Hypertension. Cells. 2023 01 14; 12(2).
-
An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis. Commun Biol. 2022 11 07; 5(1):1192.
-
Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2605-2618.
-
Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling. Int J Mol Sci. 2020 Sep 05; 21(18).
-
Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018 04 12; 9(1):1416.
-
Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-ß in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol. 2017 08; 37(8):1559-1569.
-
MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation. Vascul Pharmacol. 2016 09; 84:67-73.
-
In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug. Circulation. 2016 May 03; 133(18):1783-94.
-
RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015 Aug 01; 192(3):356-66.
-
Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors. PLoS One. 2013; 8(8):e72407.